Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbinoxamine + pseudoephedrine is a combination drug used for the **symptomatic treatment of allergies and nasal congestion**, commonly administered as an oral syrup or tablet. **Carbinoxamine** is a first-generation antihistamine of the ethanolamine class, competing with histamine for H1 receptor binding to reduce allergic symptoms, and possesses notable anticholinergic and sedative properties. **Pseudoephedrine** is a sympathomimetic amine acting as a nasal decongestant by stimulating alpha-adrenergic receptors, resulting in vasoconstriction in the nasal mucosa and thereby relieving congestion. The combination allows for immediate antihistaminic relief (carbinoxamine) and sustained decongestant effect (pseudoephedrine) over up to twelve hours. Primary indications include **allergic rhinitis** and other conditions associated with nasal allergy and congestion[1][8][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carbinoxamine + pseudoephedrine.